Intraoperative Consultations of Central Nervous System Tumors: A Review for Practicing Pathologists and Testing of an Algorithmic Approach. by Çakir, Emel et al.
UCSF
UC San Francisco Previously Published Works
Title
Intraoperative Consultations of Central Nervous System Tumors: A Review for Practicing 
Pathologists and Testing of an Algorithmic Approach.
Permalink
https://escholarship.org/uc/item/87r3834z
Journal
Turk patoloji dergisi, 35(3)
ISSN
1018-5615
Authors
Çakir, Emel
Oran, Gülbin
Yüksek, Gül Emek
et al.
Publication Date
2019
DOI
10.5146/tjpath.2018.01460
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Review
1
Received : 06.03.2019   Accepted : 09.04.2019
Correspondence: : Emel ÇAKIR
Karadeniz Technical University Faculty of Medicine, 
Department of Pathology, TRABZON, TURKEY
E-mail: emelnur7@gmail.com    Phone: +90 462 377 55 20
doi: 10.5146/tjpath.2018.01460
ABSTRACT
Intraoperative consultations or frozen sections for central nervous system (CNS) tumors present a significant challenge for surgical pathologists 
because of their relative rarity and diversity. Yet, such lesions are encountered by every surgical pathologist, and a basic understanding of clinical, 
radiological and genetic information is critical to successfully evaluate CNS frozen sections. It is often beneficial to have a systematic approach 
or an algorithm, and to be aware of the common pitfalls and mimickers when dealing with these lesions. We propose such an algorithm in an 
effort to construct a sensible approach to CNS frozen sections that considers recent developments in the WHO CNS tumor classification. The 
algorithm was developed for surgical pathologists who are occasionally faced with making diagnosis of CNS tumors on frozen sections. To test 
the algorithm and its practicability, we selected a group of tumors among a total of 3288 consecutive intraoperative consultations performed at 
UCSF between 2013 and 2017. The selected cases represented  lesions that may be encountered in everyday surgical pathology and constituted 
a fair reflection of the main group. The algorithm was used by three of the authors who did not have formal neuropathology training and had 
been in surgical pathology practice for at least 3 years. There was a very high level of concordance among the authors’ diagnosis (interobserver 
concordance: 0.83-0.97-kappa value) using the algorithm with high intraobserver reliability (concordance 93%, p<0.001).  We suggest that an 
algorithmic approach is an effective means for the surgical pathologists, and may help reach diagnosis during frozen sections. 
Key Words: Algorithm, Central nervous system tumors, Frozen section, Intraoperative consultation, Surgical neuropathology 
INTRODUCTION
Intraoperative consultation, commonly known as the 
Frozen Section (FS), is a critical function of surgical 
pathologists to help guide the management of patients 
undergoing surgical procedures. One of the main reasons 
for performing FS in patients with central nervous system 
(CNS) disease is to determine the course of action during 
surgery. In this capacity, the surgical pathologist is a key 
ally of the neurosurgeon to help select the most appropriate 
patient management. A successful FS procedure requires 
an understanding of the essential phases of the process 
while recognizing the pitfalls and limitations. A number of 
precautions have been historically recommended (1-6) in 
order to avoid mistakes and provide the greatest benefit to 
the patient: 1-good communication with all those involved, 
2- recognition of the clinical and radiological information 
by the pathologist, 3-determination of sample adequacy, 
4-appropriate tissue handling and accurate interpretation. 
The approach to FS always demands adequate communica-
tion between the neurosurgeon and the surgical pathologist 
to understand the complexities of the case and the specific 
issues about the patient. At the initial step, the request 
is to render a diagnosis and help the surgeon decide the 
course of action, but in many occasions, there may be other 
questions directed to the pathologist (1-3). The pathologist 
needs to acquire the critical clinical and radiological 
information at this initial stage and anticipate questions 
that may be critical for the specific case. 
The second step is appropriate tissue processing and 
assessment of tissue adequacy. Tissue processing typically 
involves preparing a smear and performing tissue sections 
with the help of the cryostat. Evaluation of the prepared 
smears and tissue sections can be made using an algorithm 
that helps the pathologist incorporate all the relevant 
information in order to reach the appropriate differential 
diagnosis (4). Previous studies have proposed methodical 
assessment of the information as well as evaluation of 
cytological and histological features for accurate diagnosis 
(1,2,5,6). 
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old habits should be reconsidered for a more realistic 
characterization. The most recent WHO classification 
scheme has adopted the integrated diagnosis for which 
molecular or genetic information must be considered before 
a final diagnosis is rendered (17). This approach affects 
the specificity of FS diagnosis for some entities in at least 
two aspects; first, there should be little need to subclassify 
glial tumors as oligodendroglioma or astrocytoma and to 
provide WHO grading during FS interpretation. Second, 
obtaining additional tissue for diagnostic molecular studies 
should be paramount for providing the appropriate care. 
These considerations require surgical pathologists to be 
familiar with the necessary testing (Table II) and the degree 
of specificity of the FS diagnoses. 
This introduction provides a stepwise description of key 
issues in the pre-analytical, analytical and post-analytical 
stages. It is aimed at pointing out the challenges at each 
stage of FS, and to encourage the reader to consider the 
critical stages of the process.
Stage 1- Pre-Analytical Phase
Awareness of the pertinent information that could affects 
FS interpretation is critical in the pre-analytical phase of FS. 
The clinical as well as radiological features are extremely 
helpful in constructing the list of possible diagnoses 
as well as those that would be improbable in a specific 
clinical setting. Integration of patient demographics with 
imaging helps to narrow the diagnostic possibilities, and 
collaboration with expert neuroradiologists should be the 
first choice of action. If a neuroradiologist is not available, 
the surgical pathologist is left on her/his own resources 
for the interpretation of radioimaging studies. This is 
neither optimal nor advised, and inaccurate interpretation 
of radioimaging characteristics can lead to significant 
mistakes or unrealistic diagnoses.
The combined interpretation of smears and tissue sections 
is of critical importance in order to reach the appropriate 
differential diagnosis. This combination was shown to 
significantly improve the diagnostic accuracy leading to a 
high rate of concordance with the final diagnosis (1,5,7-
10). Smears are useful, especially if the amount of sampled 
material is difficult to freeze or if the lesion is in vulnerable 
anatomic regions such as the brain stem, spinal cord and 
deep grey structures, precluding large or repeated samples 
(1). Standard H&E staining (Table I) has been the method 
of choice for both smears and tissue sections (2).
Several studies correlating FS and final diagnoses 
identified challenges in the correct recognition of tumors. 
These challenges include difficulties in distinguishing 
diffuse gliomas from reactive or inflammatory lesions, 
differentiating spindle cell tumors (e.g. meningioma vs. 
schwannoma), recognizing primary versus metastatic 
malignancies, defining grade or aggressiveness of 
meningothelial and glial tumors (5,9,11-13). In 
addition, differential diagnosis of astrocytoma versus 
oligodendroglioma, lymphoma versus other small-blue-
round-cell tumors, and diffuse versus non-infiltrating low 
grade glial neoplasms have been historically challenging 
(5,7,11,14,15). Non-neoplastic lesions have often been 
overlooked since they are less commonly sampled for FS 
and therefore less familiar to surgical pathologists. The 
most common non-neoplastic lesions often mistaken 
for neoplasms include demyelinating lesions, infections, 
dysplastic lesions such as focal cortical dysplasia, 
radiation-associated changes, vascular malformations, and 
hemorrhages (16).
Recent developments in the classification of CNS tumors 
underscore the need to revise the decades old approach to 
FS of CNS tumors, and to reconsider what could be reliably 
reported during the intraoperative consultation, and what 
Table I: Standard H&E staining protocol for smears and frozen sections.
•	Fix the smear or tissue section slide on methanol/ethanol mixture for at least 30 seconds and transfer into slide holders
Station 1 Immerse the entire tissue into Hematoxylin solution for a minimum of 30 seconds with agitation- then thoroughly rinse in water
Station 2 Immerse in 1% HCl to remove excess hematoxylin for 10 seconds (5-10 dips) - then thoroughly rinse in water
Station 3 Place into Ammonia solution to develop blue color of hematoxylin for 10 seconds (5-10 dips)
Station 4 Stain with Eosin solution for a minimum of 15 seconds (slow 10-15 dips)
Station 5 Clear the slide in 95 % ethanol twice for 10 seconds (two jars) and then twice in 100% ethanol for 10 seconds (two jars)
Station 6 Wash in Xylene twice (two jars) until completely clear changing jars ( 2 x 5-10 dips)
•	Immediately cover the slide using mounting media
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One of the most critical issues in every stage of the FS 
is clear, unambiguous and effective communication 
among the stakeholders of this consultative process. This 
communication should involve the neuropathologist and 
the neurosurgeon in as much direct fashion as possible. 
The most efficient ways to achieve this communication is 
an actual visit to the operating room by the pathologist, 
where he/she can directly communicate with the 
neurosurgeon, understand the critical issues concerning 
the case, find out about the clinical details, past history, and 
prior treatment(s). Access to diagnostic imaging studies 
is always possible in the operating room, which saves the 
pathologist the extra effort to learn the imaging features 
of the case. The combination of clinical, radiological and 
operative findings is sometimes pathognomonic, and 
will only require simple visual microscopic confirmation 
by the surgical pathologist. On the other hand, clinically, 
radiologically and surgically challenging cases will often be 
a harbinger of difficulty at the microscope. 
Communicating the critical patient information to the 
pathologist is very important and the surgeons and 
clinicians should recognize the need to provide their 
perspective, since the surgical pathologists are not experts 
in clinical, neuroradiological or neurosurgical practices and 
nuances. While the surgical pathologist must actively seek 
this information, he/she should also educate others about 
the importance of providing the pertinent information for 
an accurate FS diagnosis.
Another critical issue in the first stage is the correct 
recognition of the tissue sample and patient identification. 
Each system must develop a reliable chain-of-custody 
procedure to ensure timely and efficient delivery of the 
correct tissue samples from the operating room to the 
pathology laboratory. 
Stage 2- Analytical Phase
The surgical pathologist should be familiar with the 
situations that may lead the process astray in the analytical 
phase, and must have a good understanding of the tissue 
processing steps in order to identify/avoid errors.  The 
critical elements of this stage include appropriate tissue 
procurement, processing and interpretation. Many studies 
report that the use of intraoperative smears significantly 
improves the diagnostic accuracy (1, 7). Therefore, use of 
smears and the ability to interpret the features in smears are 
critical. Certain nuclear and cytoplasmic details of tumor 
cells are best appreciated on smear preparations. However, 
smears do not permit a detailed assessment of architectural 
features and the nature of the tumor-brain interface.  Tissue 
sections provide better information on the architectural 
features, cellularity and extracellular environment. 
Ideally, a well-prepared smear, a good tissue section and 
sufficient material for subsequent critical studies (final 
diagnosis) must be obtained prior to the analytical process. 
Sufficient material for special studies and molecular 
analyses are required as a standard of care for increasingly 
Table II:  CNS Tumors that require molecular analysis for integrated diagnosis (therefore require extra caution when making the 
diagnosis during frozen sections).
Tumor Type Molecular Marker Required
Diffuse Astrocytoma, IDH-mutant 
including Glioblastoma, IDH-mutant
IDH1, ATRX, p53 immunohistochemistry, IDH1/2 sequencing (if 
necessary)
Diffuse Astrocytoma, IDH-wildtype 
including Glioblastoma, IDH-wildtype EGFR, PTEN, TERT alterations, Chr7 gain and Chr 10 loss
Oligodendroglioma
IDH1 immunohistochemistry, 
IDH1/2 sequencing (if necessary)
Chr 1p/19q co-deletions 
Diffuse midline glioma H3 K27M, H3K27me3 immunohistochemistry
Medulloblastoma, WNT-activated B-catenin, ALK, LEF1, YAP 1 immunohistochemistry
Medulloblastoma, SHH-activated GAB1, YAP1 immunohistochemistry
Atypical Teratoid/Rhabdoid Tumor SMARCB1 (BAF47), SMARCA4 (BRG1) immunohistochemistry
Embryonal Tumor with Multilayered 
Rosettes
LIN-28A immunohistochemistry
C19MC sequencing
Solitary Fibrous Tumor/
Hemangiopericytoma STAT6 immunohistochemistry
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large number of tumor types in the molecular era (1). 
There is an ever growing list of tumors that will benefit 
from molecular analysis and a larger number of genetic 
alterations that are helpful for the diagnosis of tumors, 
yet a short list can be generated for tumors that MUST be 
characterized in terms of their molecular characteristics 
required for the WHO 2016 integrated diagnosis (Table 
II). In circumstances where the tissue is too small to be 
sufficient for all of the above, the priority should be given 
to preserve the tissue for an accurate final diagnosis using 
permanent sections.
Difficulties of interpretation can be due to multiple factors 
including limited sampling, inadequate information, 
processing problems, and inexperience. Any tumor can 
be morphologically heterogeneous, and accurate diagnosis 
highly depends on adequate sampling. Insufficient tissue, 
necrotic material or non-representative tissue often does 
not permit an accurate diagnosis and further material 
should be sought. When large specimens are submitted, 
gross visual examination and recognition of the normal 
gray and white matter as well as the abnormal tissue allows 
a better and more appropriate sampling for FS diagnosis 
(1). To prevent sampling errors, multiple smears and tissue 
sections may be necessary, as long as there is sufficient 
material for final diagnosis and molecular studies. Some 
studies show that a minimum of 4 tissue samples may be 
necessary to ensure a high diagnostic yield (1,18,19).
Preparation of a good smear is a crucial part of sample 
preparation. A tissue fragment, not to exceed 2 mm should 
be used. This tissue fragment is placed on the glass slide 
closer to the label side, and the fragment is “smeared” by 
gentle pressure using another glass slide and dragged along 
the length of the slide. The slides should be dipped and 
fixed in 95% ethanol for at least 15 seconds immediately 
after smearing. No air drying should be permitted. 
The frozen section should be performed with utmost care 
to avoid over-freezing or drying. In addition, the tissue 
should not be allowed to “bathe” in water or saline, and 
preferably should be placed on a tissue paper wetted with 
isotonic solutions. A frozen metal block and optimal 
cutting temperature (OCT) compound could be used to 
mount the tissue on the cryostat and no thicker than 5 
micron sections should be obtained containing the entire 
cut surface of the tissue sample. One important point about 
the OCT compound is the ability of this mixture to inhibit 
the PCR reaction, and to render the tissue inappropriate for 
some molecular studies. The staining for smears and tissue 
sections can be made with the same standard H&E protocol. 
Since different H&E staining protocols may influence the 
quality of the interpretation, an optimal staining protocol 
is provided on Table I.
Once the smears and tissue sections are optimally prepared, 
the surgical pathologist should begin the interpretive task 
using a set of standard questions (Figure 1) and a systematic 
assessment of microscopic features; i.e. an algorithm (Figure 
2A,B). The initial question should focus on the normal and 
abnormal elements in the sample (Is the tissue abnormal 
and are there normal cells?) followed by the inquiry as 
to whether the sample is actually representative of the 
process (Is the specimen sufficient and representative?). 
A negative answer to either of these questions require an 
early remediation such as repeating the smear or the tissue 
section or requesting additional tissue from the operating 
room. Once both questions are answered affirmatively, 
the next step in the algorithm is to distinguish between 
a neoplastic and non-neoplastic process (Is it neoplastic 
or non-neoplastic?). Once the lesion is recognized as 
neoplastic, the algorithm (Figure 2A,B) can be employed 
to further characterize the process. Naturally, since the 
probabilities vary between the pediatric and adult patients, 
the algorithm should be modified accordingly (Figure 
2A,B). The step in which the neoplastic/non-neoplastic 
decision is made can be deceptive and unexpectedly 
difficult.
Figure 1: The algorithm of intraoperative consultation specimens 
for CNS tumors.
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The first step of the algorithm (Level 1) is to recognize the 
smear and frozen section background as belonging to one 
of the four basic patterns; predominantly glial, neuronal, 
mesenchymal or epithelial (Figure 2A,B). The second 
step (Level 2) is the analysis of cytological features of the 
“abnormal” cells in terms of nuclear morphology (Level 
2a) and cytoplasmic characteristics (Level 2b). Nuclear 
morphology is evaluated in terms of hyperchromasia, 
pleomorphism, nucleoli, structural anomalies such as 
grooves or inclusions. Cytoplasmic characteristics include 
definition of cellular membranes, processes, cytoplasmic 
structural anomalies (folding, inclusions, vacuolization). 
The third step includes review of architectural features in 
the smear and tissue sections (Level 3).
The recognition of the smear and tissue background 
features can allow the surgical pathologist to create shorter 
lists of differential diagnosis and help construct a practically 
relevant interpretation for the surgeon (Is the tumor glial 
or non-glial). In addition, level 1 categories can be further 
subdivided into diagnostically relevant subgroups based on 
Figure 2: A) An algorithmic 
approach to adult patients 
with CNS tumors. 
B) An algorithmic approach 
to pediatric patients with CNS 
tumors.
A
B
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cytological and architectural observations as being indolent 
or aggressive nature. Histologically benign appearing lesions 
can be distinguished from histologically and cytologically 
anaplastic or malignant samples. The cytological and 
architectural features from both the smear and the tissue 
section can be used to determine whether the neoplasm is 
aggressive or more likely to be indolent (Is it high grade or 
low grade?). The next step after the interpretation of the 
background as glial is the recognition of signs that suggest 
aggressive biology as well as infiltrative or solid growth 
pattern. Figure 2A and 2B provide a differential diagnosis 
of tumors based on information gathered at levels 2-3.
Some typical histological features may be difficult to 
recognize on FS. For example, the features typical of 
oligodendrogliomas such as the “chicken-wire” vasculature 
and “fried-egg” cells are due to paraffin processing and not 
readily recognizable on FS. Freezing also imparts significant 
artefactual changes in tumors such as oligodendrogliomas, 
rendering them difficult to distinguish from other gliomas 
(Figure 3A-C). While nuclear features and chromatin 
structure may be helpful in telling them apart, recent 
molecular studies imply that it may not be possible to make 
this distinction easily on morphological grounds. With 
the changes suggested in the WHO 2016 classification, it 
may be sufficient to recognize the tumor simply as “diffuse 
glioma”, and avoid the problem of the astrocytoma vs. 
oligodendroglioma distinction during FS altogether. For 
histologically malignant lesions, it may be sufficient to 
express the presence of a “high grade glioma”, especially if 
multiple mitotic figures, vascular proliferation or palisading 
necrosis is present.
Figure 3: A) Oligodendroglioma, smear – Intraoperative smear preparation of IDH-mutant, 1p/19q co-deleted oligodendroglioma. The 
smear preparation highlights the glial (fibrillary) background, round nuclei, scant cytoplasm and absence of mitotic activity (H&E; 
x400). B) Oligodendroglioma, frozen - The frozen sections from oligodendrogliomas often do not exhibit the typical chicken-wire 
vasculature and perinuclear halos that are associated with formalin fixation and paraffin embedding. Nevertheless, the delicate, thin 
vascular channels that portend the tumor its chicken-wire vasculature can be appreciated (H&E; x200). C) Oligodendroglioma, frozen 
–Frozen sections in low grade oligodendrogliomas may be subjected to significant freezing artifact, rendering assessment of cellularity 
and nuclear morphology impossible. Without smear preparations, such frozen sections can be ver difficult to interpret (H&E; x200). 
D) Schwannoma, smear – Schwannomas are among tumors that are difficult to smear. Elongated, irregular nuclei, inconspicuous nucleoli 
and a mesenchymal type background are distinctive features in smear preparations (H&E; x400). E) Meningioma, smear – The smear 
preparations of meningiomas demonstrate the prototypical “mesenchymal background” with abundant cytoplasmic folding creating the 
so-called “train-track” appearance. The nuclei are often round to oval with intranuclear inclusiong and open chromatin pattern, (H&E; 
x400)- Inset 1 –Traintracks;  Inset 2- Intranuclear inclusion, (original magnification ; x1000). F) Solitary fibrous tumor, smear – Similar to 
meningiomas, solitary fibrous tumors have a typical “mesenchymal” background with prominent fragments of collagen and spindle cells 
with ovoid or round nuclei. Features such as intranuclear inclusions, train tracks or nuclear grooves are absent (H&E; x400). 
A
D
B
E
C
F
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Tumors with neuronal background are often in the glioneu-
ronal, neurocytic or embryonal category, with the exception 
of samples obtained from the periphery of diffuse gliomas 
containing substantial amount of neuropil. While the 
background in such samples of diffuse gliomas may appear 
neuronal, the glial characteristics of the tumor are almost 
always prominent in smears and tissue sections, allowing 
the surgical pathologist to recognize diffuse glioma. The 
differential diagnosis of smears with neuronal background 
should also include embryonal tumors, especially in pediat-
ric patients. Level 2 and 3 observations will identify malig-
nant or “high grade” features in these tumors.
Distinguishing spindle cell neoplasms such as meningioma, 
schwannoma or solitary fibrous tumor can be challenging 
on FS. These spindle cell tumors are very similar on clinical 
and radiological grounds. On level 1 all such lesions have a 
mesenchymal background, yet cytological and architectural 
clues may help to distinguish them from one another 
(11). Finding isometric, round or oval nuclei with the 
“train track sign” is suggestive of a meningioma, whereas 
a tumor with markedly irregular, pleomorphic nuclei and 
highly cohesive tissue clusters may suggest schwannoma. 
Most often, however, the differential diagnosis of benign 
mesenchymal tumors is not of practical significance. The 
FS diagnosis can simply be “spindle cell neoplasm, no high 
grade features” and the specific diagnosis may be deferred 
to permanent sections, especially for difficult lesions that 
appear fibroblastic (Figure 3D-F).
If the background of the smear is not appropriately 
recognized, the interpretation of a small blue round cell 
tumor can be quite challenging on FS. Such tumors can 
be embryonal neoplasms, lymphomas, malignant gliomas, 
anaplastic ependymomas, or metastatic carcinomas, 
neuroendocrine tumors or small cell sarcomas. A careful 
review should identify the nature of the background and 
allow recognition of ependymal, glial, or embryonal 
tumors. Metastatic carcinomas would yield a dirty epithelial 
background, while melanomas or sarcomas have partial 
mesenchymal background characteristics.
Stage 3- Post-Analytical Phase
The critical function of the surgical pathologist during the 
post-analytical phase is the accurate and timely reporting 
of the FS diagnosis. It is not appropriate to argue about the 
necessity of any intraoperative consultation during surgery, 
and the surgical pathologist could convey the ambiguity of 
making certain diagnoses on FS to the neurosurgeon at a 
less stressful time.  
In the past, it has often been the custom to report whether 
a diffuse glioma was astrocytic or oligodendroglial, as 
well as mention the presumed WHO Grade. Today, 
understanding the genetic diversity and the importance 
of IDH, ATRX, PT53 mutations as well as TERT, EGFR 
and PTEN alterations forces us to be less definitive on the 
type and grade of diffuse gliomas during FS. The presence 
of nuclear atypia without aggressive histological features 
is often little comfort, especially if the patient is older 
(typically >65 years) or if there are worrisome radiological 
features. Reporting of diffuse gliomas that appear low 
grade on histology should always be made with caution 
since a subsequent sample may show higher grade features 
(20). Studies highlight the caveat of undergrading tumors 
in small samples or during FS procedures (3,11). 
Tumors with clearly malignant or anaplastic features such 
as numerous mitoses, vascular endothelial proliferation 
(microvascular proliferation) or necrosis with or without 
palisading are important clues for the recognition of a 
“high grade glioma”.  All these features must also consider 
the importance of establishing an integrated final diagnosis 
consistent with WHO 2016 criteria (see below).
Recognition of the mesenchymal or spindle cell features 
may allow the pathologist to suggest a spindle cell tumor 
without high grade features, which may be sufficient for 
the patient management intraoperatively. While it may 
be helpful to distinguish meningioma from schwannoma 
or from a solitary fibrous tumor later, such distinctions 
can easily be deferred to permanent sections. Grading of 
spindle cell neoplasms such as meningiomas should be 
avoided on FS.
In case of highly malignant neoplasm with a primitive 
appearance, i.e. small-blue-round cell tumors, there is a good 
reason to be able to sort out what type of primitive tumor 
has been sampled.  Primary neuroepithelial tumors should 
be distinguished from malignant lymphomas or metastatic 
tumors. If this distinction is not clear, the diagnosis is 
essentially a deferral to permanent sections, and will most 
certainly require special studies. Clinical and radiological 
features must be evaluated with caution, and the age of the 
patient should be taken into consideration when reporting 
these lesions. It is also critical to directly communicate with 
the neurosurgeon, because it may be sufficient to render 
a diagnosis of “neoplasm” for practical purposes, and the 
neurosurgeon may not need the pathologist to agonize over 
a difficult, and often an impossible differential diagnosis. 
What has changed with WHO 2016?
Many modifications of the WHO 2016 CNS tumor 
classification and the subsequent clarifications have 
changed the way FS diagnosis can be reported, and the two 
major groups affected by these modifications are glial and 
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embryonal tumors. A few points need to be made about 
some diagnostic statements that can be used in compliance 
with this classification:
• Diffuse glioma, no high grade features: Once the 
tumor is identified as infiltrating or diffuse glioma, it 
may not be necessary to subclassify tumors as either 
astrocytoma or oligodendroglioma. Especially if there is 
no radiological or histological evidence of a high grade 
tumor, the FS diagnosis could be “diffuse glioma, no 
high grade features”. Since there is always the possibility 
of finding a higher grade component on permanent 
sections, the statement of “no high grade features on 
FS” may be used instead of “low grade diffuse glioma” 
to avoid giving the impression that the FS diagnosis 
suggests a final grade. It is more prudent to be remain 
in a more general diagnostic category for the cases 
that will typically require further genetic/molecular 
characterization. 
• Diffuse glioma, high grade: For tumors with glial 
background, radiological and clinical features are 
critical to determine their aggressive potential. Most 
diffuse gliomas in the elderly, diffuse gliomas with 
substantial (or ring) enhancement on MRI, histological 
features such as vascular proliferation and necrosis are 
most often high grade tumors. Histological evidence 
of malignancy should prompt “Diffuse glioma, high 
grade” designation. However, even in the absence of 
histological evidence, the clinical and radiological 
evidence may allow the pathologists to report the 
tumor as “Diffuse glioma, favor (or suspect) high grade 
tumor”. Diffuse gliomas in the midline with H3K27M 
mutations are also considered WHO grade IV lesions, 
so the possibility of this type of tumor may also lead 
the pathologist to “favor or suspect” high grade diffuse 
glioma.
• Low grade glioma, NOS: This nonspecific diagnosis 
would imply a number of diagnostic possibilities and 
is not appropriate as a final diagnosis. However, solid 
tumors with no sign of aggressive features radiologically 
and histologically may be reported as “Low grade 
glioma” and a discussion with the surgeon about the 
non-infiltrative nature of the tumor should be made. 
This designation is best avoided for diffuse gliomas, 
regardless of their FS appearance. For cases when a 
diffuse glioma cannot be entirely excluded, it is best to 
DEFER the diagnosis, since the designation of diffuse 
versus non-infiltrative/solid tumor is an important one. 
• Embryonal Tumor, NOS: The term embryonal tumor 
has replaced the old “primitive neuroectodermal tumor” 
category, and there is a larger list of tumor entities in 
this group. Most embryonal tumors in the cerebellum 
are diagnosed as medulloblastoma. However, before 
one can clearly use this diagnosis, it is imperative to be 
certain that it cannot be one of the recently described 
tumor entities such as the embryonal tumor with 
multilayered rosettes (ETMR), or atypical teratoid/
rhabdoid tumor (AT/RT). All of these tumors have a 
neuronal-like background with small-blue-round cells, 
but each has somewhat unique feature that may not be 
readily apparent in FS. For tumors in the posterior fossa, 
“embryonal tumor, favor/suggest medulloblastoma” 
may be a better option than a simple “medulloblastoma” 
since there are overlaps with the entities mentioned 
above. In the rare supratentorial example, the 
differential diagnosis includes even more entities, so 
“embryonal tumor” or “embryonal tumor, NOS” could 
be the diagnosis of choice until a better classification 
is made on permanent sections. One important issue 
in the differential diagnosis is recognizing pediatric 
ependymal tumors within the posterior fossa that could 
easily be confused with medulloblastoma. 
• Tissue for Molecular studies: Ever increasing number of 
tumors require molecular characterization for accurate 
typing and grading, and providing sufficient tissue for 
these analyses is very important. It is imperative to be 
aware of these tumors, secure enough material for the 
appropriate studies, and alert the surgeon to the need 
of extra tumor tissue for these studies during the FS 
procedure. Tumors in this category may include all 
diffuse gliomas including glioblastoma, all embryonal 
tumors in the pediatric population, tumors with both 
glial and neuronal elements, and any tumor that the 
pathologist finds problematic in characterizing with 
a high degree of confidence. A minimalistic list of 
molecular studies would include IDH, ATRX, TP53, 
H3K27M, H3G34R/V, SHH, WNT, BRAF, CTNNB1, 
SMARCB1 mutations MYC, C19MC, RELA, BRAF, 
BCOR, MN1 rearrangements and chromosomes 1, 7, 
10, 19 alterations. This list could be expanded and is 
growing with every passing day.
Testing The Algorithm: Practical Utility
Method: To determine its practical utility, the algorithm 
was tested by three of the authors without formal 
neuropathology training on a group of cases selected 
from 3288 FS procedures performed in our institution 
between 2013 and 2017. We reviewed all the FS procedures 
during this period to acquire a sense of the frequency 
and distribution of diagnoses and types of cases in our 
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institution. Clinical and radiological information, original 
FS diagnoses, and final pathology diagnoses for all cases 
were reviewed by two of the authors (EC, TT). A subset 
of 160 cases was selected by one of the authors (GEY) for 
testing the algorithm by three of the authors (EC, GO, 
CD). Each diagnosis was rendered by one of the authors. 
The subset of cases for the study were identified among 
cases with sufficient clinical and radiological information. 
Original FS diagnoses were recorded for all cases, and the 
final diagnoses were confirmed through additional special 
studies and clinical follow-up information. The final 
diagnoses for each case was considered the gold standard 
(i.e. correct diagnosis). Three of the authors reviewed 
the smears and tissue sections as well as the clinical 
information that was available at the time of the original FS. 
In addition, 30 of the cases were used in an interobserver 
variability study. Each pathologist was asked to use a 
checklist composed of the algorithmic steps (Figures 1, 
2A,B) and to provide the diagnosis for which they felt 
confident enough to report to the neurosurgeon.  The use 
of the algorithm required selecting options from a decision 
tree and to identify a diagnostic category. The diagnoses 
were then compared to the original FS diagnoses as well 
as the final diagnoses. Concordance and interobserver 
variability were evaluated to determine the effectiveness of 
the algorithm. Discrepancies were defined as either major 
or minor. Major discrepancy was defined as a difference 
between two diagnoses (original FS versus final diagnosis; 
algorithmic FS versus original FS diagnosis; algorithmic FS 
versus final diagnosis) that would significantly alter patient 
care, a change in the major diagnostic groups in the WHO 
classification, or a change in WHO grade of more than 
1 level (e.g. WHO grade I to grade III or II to IV, or vice 
versa). Minor discrepancy was defined as a change within 
major diagnostic groups or a change in the WHO grade of 
one (1) level AND no potential adverse effect on patient 
care.
Statistical analyses were performed using the SPSS Version 
23 with Advanced Statistics Package. The McNemar Test 
was used in the analysis of the differences between the 
ratios of categorical variables in independent groups. The 
Kappa Test was used to evaluate interobserver agreement 
by the Online Kappa Calculator (21). The concordance 
between authors’ diagnosis, original frozen diagnosis and 
final diagnosis were tested by Intraclass Correlation Test 
and presented with 95% confidence intervals. A p value 
less than 0.05 was considered statistically significant. This 
study was approved by the UCSF Committee for Human 
Research (CHR 10-01252).
RESULTS and DISCUSSION
The distribution of all FS cases between 2013 and 2017 is 
presented in Figure 4. The most common tumors were 
Glioblastoma (702 cases; 21.3%), meningiomas (541 cases; 
16.5%), and diffuse astrocytic tumors (348 cases; 10.5%). 
Among those, 160 cases were randomly selected by one 
of the authors and the other authors were blinded to the 
selection process. 
There were 9 cases with major and 12 cases with minor 
diagnostic discrepancies between the algorithm-based 
diagnosis (author’s diagnoses) and the final diagnosis 
Figure 4: The frequency of each 
tumor entity among all FS cases 
between 2013 and 2017.
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(major discrepancy rate (5.6%). These discrepancies are 
presented on Table III. In addition, 12 cases showed major 
discrepancies between the original and the algorithm-
based FS diagnoses. In addition, there were a total of 6 
discrepancies between the original frozen diagnosis and final 
diagnosis (discrepancy rate 3.8%). Two of these diagnoses 
were rendered by surgical pathologists (neuropathologist 
discrepancy rate %2.5). Two of the original frozen section 
diagnoses were deferred to permanent sections (deferral rate 
1.25%). Others were associated with grading or inadequate 
sampling. The concordance analysis is presented on Table 
IV.
Seven of the 9 major discrepancies fell into a particular 
type where the algorithm diagnosis and final diagnosis 
differed in neoplastic versus non-neoplastic diagnoses. The 
interobserver concordance was high among the authors, 
and the differences often emerged at level 4, when the 
pathologists were asked to select a specific diagnosis from 
the final list. Nevertheless, interobserver variability was 
quite low with high concordance in most tumor categories 
(Table V).
Using the algorithm during the mock FS procedures 
helped identify general categories of tumors more easily 
and provided a standard checklist to remember. While 
this was difficult to quantify, specific questions and in the 
algorithm allowed pathologists to consider the options 
not considered originally in their differential diagnosis. 
Recognizing the smear background also allowed to start 
with a narrower list of differential diagnosis. The algorithm 
also led the pathologists to better define low grade and 
high grade features within the same categories. This was 
particularly helpful since in many occasions, the surgeons 
may be satisfied with a descriptive diagnosis or a category 
rather than a specific entity. 
Table IV: Concordance between authors’ diagnoses and original frozen and final diagnoses.
Ca
se
s (
n=
16
0)
Diagnostic Category Based on the Algorithm 
(authors’ diagnoses)
Agreement with frozen 
diagnosis  %
Agreement with final 
diagnosis %
Non-neoplastic lesions 77.8 88.0
Pituitary adenomas 100.0 100.0
Benign mesenchymal tumors 88.5 95.8
Metastatic tumors 90.0 90.0
High grade neuroepithelial tumors 90.4 90.7
Low grade neuroepithelial tumors 85.2 85.2
Others 88.9 100.0
Intraclass Correlation  (95% C.I., p) 89.93 (86.2-92.7), p<0.001 89.90 (86.2-92.7), p<0.001
Table III: Major discordance between authors’ diagnosis and the final diagnosis.
Case # Authors’ diagnosis Original frozen diagnosis Final diagnosis
Case 20 Non-neoplastic Diffuse Astrocytoma Anaplastic Astrocytoma
Case 40 Non-neoplastic Possible Lymphoma Glioblastoma
Case 50 Non-neoplastic Diffuse Astrocytoma Diffuse Astrocytoma
Case 59 Benign mesenchymal tumor, NOS Non-neoplastic, acute inflammation Osteomyelitis with epidural abscess
Case 75 Anaplastic Astrocytoma Recurrent Oligodendroglioma Recurrent Oligodendroglioma WHO Grade II
Case 76 Glioma, NOS Non-neoplastic Radiation necrosis
Case 123 Malignant neoplasm, NOS Malignant neoplasm, NOS Central Neurocytoma
Case 126 Low grade glioma Non-neoplastic Focal Cortical Dysplasia
Case 131 Non-neoplastic Suspicious for low grade Chondrosarcoma Low Grade Chondrosarcoma
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In the present study, the pathologists using the algorithm 
most often misdiagnosed non-neoplastic lesions, since the 
algorithm had focused on identifying tumors and the non-
neoplastic possibilities were often overlooked (7 of 9 major 
discrepancies). This was interpreted as a typical cueing 
error, since the participants were focused on identifying 
the type of tumors in the slides. This was particularly 
important because once the surgical pathologists 
committed themselves to either a neoplastic process, it 
was very difficult to change course. Therefore, the most 
critical stage prior to the application of the algorithm 
was recognized as the first stage when the question “is it 
neoplastic or non-neoplastic?” is being determined. This 
was also due to the fact that the number of non-neoplastic 
lesions is often very low in surgical pathology practice, and 
the recognition of the non-neoplastic lesions often requires 
keeping them in mind and being familiar with their frozen 
section appearance.
The two other major discrepancies were related to the grade 
of the neoplasm (is it high grade or low grade?). However, 
one of the critical issues in this exercise was the limited 
amount of information, and in both cases, the pertinent 
clinical information not immediately available during 
frozen section (prior diagnosis of oligodendroglioma in one 
case and radiological diagnosis of central neurocytoma in 
the other). In real life, it would have been easier to correctly 
diagnose these cases.
While there were other minor discrepancies related to 
individual factors, the authors have reached a differential 
list containing the correct diagnosis in the overwhelming 
majority of the cases. The algorithm was not fool-proof, and 
additional information and scrutiny would have certainly 
helped in the discrepancies. Due to the nature of the study, 
there was no opportunity to contact the clinician or review 
radiological findings or further scrutinize the cases, which 
makes us believe that the discrepancies could have been 
minimized if the suggestions above for the pre-analytical 
phase could be followed.
One limitation in this study is the potential cuing or bias 
that may be present among the observers. While each 
pathologist independently reviewed the slides and used 
the algorithm, they communicated freely and routinely 
during their daily practice while conducting the study. 
This interaction could have introduced a certain level of 
bias in the use of the algorithm, leading to a high level of 
interobserver concordance. Further studies will be needed 
to determine the interobserver variability and utility of the 
algorithm among pathologists working in different settings 
and independent of each other.
One of the other limitations of this validation study is the 
lack of comparison with other algorithms or attempt at 
diagnosis without an algorithm. However, the participants 
in this study preferred to use guidance for frozen section 
diagnosis, since they had already begun analysis with the 
algorithm. Therefore, they could not be used as unbiased 
observers. Currently, studies are being designed to 
evaluate this algorithm in different settings, larger samples 
and the actual practice environment to better define 
the contribution of the algorithm to the confidence of 
pathologists for CSN frozen sections.
Table V: Interobsever variability.
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ns Categories
%
 w
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gn
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is
Agreement with 
Author 1
Agreement with 
Author 2
Agreement with 
Author 3
Non-neoplastic 100.0 83.3 83.3
Pituitary adenomas 100.0 100.0 100.0
Benign mesenchymal tumors 100.0 100.0 100.0
Metastatic tumors 100.0 100.0 100.0
High grade neuroepithelial tumors 86.7 93.3 100.0
Low grade neuroepithelial tumors 100.0 80.0 80.0
Other tumors 100.0 100.0 100.0
Intraclass correlation (95% C.I., p) 96.0 (91.7-98.1) p<0.001
95.3 (90.1-97.7) 
p<0.001
95.5 (90.5-97.8)   
p<0.001
Concordance between authors’ diagnoses  (95% C.I.) = 93.1(87.4-96.5), [p<0.001] 
Concordance between all authors’ and frozen diagnoses (95% C.I.)= 96.3(93.6-98.1), [p<0.001]
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CONCLUSION
During the FS process, the errors made in deciding tumor 
versus no tumor may lead to erroneous diagnoses, so this 
step should be made very carefully, and any algorithm is of 
little use once the pathologists chooses the wrong option 
at this stage. Discrepancies can also occur due to sampling 
and inadequate information, and the algorithm would be 
of no use in these circumstances either. Once these hurdles 
are overcome, an algorithm can be a good learning tool and 
may help the pathologist to consider all the realistic options. 
While our initial “test” of the algorithm is quite limited and 
in no way should reflect the practicability of the algorithm 
on a larger scale, it does provide us with a helpful tool. We 
also felt that it was critical to reiterate the changes imposed 
by the new WHO classification and further revisions by 
C-IMPACT NOW publications (20,22,23) and to use this 
review to bring these changes to attention. We hope that 
our review will help the practicing surgical pathologists 
when they encounter a CNS tumor for FS in their everyday 
practice.
REFERENCES 
1. Lee HS, Tihan T. The basics of intraoperative diagnosis in 
neuropathology. Surg Pathol Clin. 2015;8:27-47.
2. Burger PC. Smears and Frozen Sections in Surgical 
Neuropathology. Baltimore/Maryland: Medical Publishing; 
2009. 184.
3. Somerset HL, Kleinschmidt-DeMasters BK. Approach to the 
intraoperative consultation for neurosurgical specimens. Adv 
Anat Pathol. 2011;18:446-9.
4. Folkerth RD. Smears and frozen sections in the intraoperative 
diagnosis of central nervous system lesions.  Neurosurg Clin N 
Am. 1994;5:1-18.
5. Savargaonkar P, Farmer PM. Utility of intra-operative 
consultations for the diagnosis of central nervous system lesions. 
Ann Clin Lab Sci. 2001;31:133-9. 
6. Kleinschmidt-DeMasters BK, Prayson RA. An algorithmic 
approach to the brain biopsy—part I. Arch Pathol Lab Med. 
2006;130:1630-8.
7. Roessler K, Dietrich W, Kitz K. High diagnostic accuracy of 
cytologic smears of central nervous system tumors. A 15-year 
experience based on 4172 patients. Acta Cytol. 2002;46:667-74.
8. Firlik KS, Martinez AJ, Lunsford LD. Use of cytological 
preparations for the intraoperative diagnosis of stereotactically 
obtained brain biopsies: A 19-year experience and survey of 
neuropathologists. J Neurosurg. 1999;91:454-8.
9. Al-Ajmi R, Al-Kindi H, George M, Thomas K. Correlation 
of intraoperative frozen section report and histopathological 
diagnosis of central nervous system tumors – a six-year 
retrospective study. Oman Med J. 2016;31:414-20.
10. Martinez AJ, Pollack I, Hall WA, Lunsford LD. Touch 
preparations in the rapid intraoperative diagnosis of central 
nervous system lesions. A comparison with frozen sections and 
paraffin-embedded sections. Mod Pathol. 1988;1:378-84.
11. Plesec TP, Prayson RA. Frozen section discrepancy in the 
evaluation of central nervous system tumors. Arc Pathol Lab 
Med. 2007;131:1532-40. 
12. Chaturvedi S, Pant I, Dua R, Gupta S. Analyzing agreement 
patterns of intraoperative central nervous system lesion reporting 
according to type and grade. J Cytol. 2013;30:179-84.
13. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. 
“Malignancy” in meningiomas: A clinicopathologic study of 116 
patients, with grading implications. Cancer. 1999;85:2046-56. 
14. Taratuto AL, Sevlever G, Piccardo P. Clues and pitfalls in 
stereotactic biopsy of the central nervous system. Arc Pathol Lab 
Med. 1991;115:596-602.
15. Powell SZ. Intraoperative consultation, cytologic preparations 
and frozen section in the central nervous system. Arch Pathol 
Lab Med. 2005;129:1635-52.
16. Plesec TP, Prayson RA. Frozen section discrepancy in the 
evaluation of nonneoplastic central nervous system samples. 
Ann Diagn Pathol. 2009;13:359-66.
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO 
Classification of the Tumours of the Central Nervous System. 
Revised 4th ed. Lyon: IARC; 2016.
18. Jain D, Sharma MC, Sarkar C, Deb P, Gupta D, Mahapatra AK. 
Correlation of diagnostic yield of stereotactic brain biopsy with 
number of biopsy bits and site of lesion. Brain Tumor Pathol. 
2006;23:71-5.
19. Brainard JA, Prayson RA, Barnett GH. Frozen section evaluation 
of stereotactic brain biopsies: Diagnostic yield at the stereotactic 
target position in 188 cases. Arch Pathol Lab Med. 1997;121:481-
4. 
20. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins 
RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, 
Stupp R, von Deimling A, Weller M: cIMPACT-NOW update 3: 
recommended diagnostic criteria for “Diffuse astrocytic glioma, 
IDH-wildtype, with molecular features of glioblastoma, WHO 
grade IV”. Acta Neuropathol. 2018;136:805-10.
21. Randolph JJ. Online Kappa Calculator [Computer software]. 
Retrieved from http://justus.randolph.name/kappa. 2008
22. Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, 
Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick 
W, van den Bent M: cIMPACT-NOW update 1: Not Otherwise 
Specified (NOS) and Not Elsewhere Classified (NEC). Acta 
Neuropathol. 2018;135:481-4.
23. Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger 
D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, 
Wick W, Wesseling P: cIMPACT-NOW update 2: Diagnostic 
clarifications for diffuse midline glioma, H3 K27M-mutant and 
diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta 
Neuropathol. 2018;135:639-42.
